Published in Hepatitis Weekly, March 1st, 2004
The net loss applicable to common stock for the first quarter totaled $9.9 million, or $0.35 per share, compared to a loss applicable to common stock of $9.3 million, or $0.40 per share, for the same period of the prior year. The current-quarter increase in net loss primarily resulted from the company's ongoing research and development activities, which included the recent regulatory filing for European approval to market Ceplene.
At December 31, 2003, the company had cash, cash equivalents, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.